Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

医学 免疫学 CD8型 胰腺癌 T细胞 抗原 免疫疗法 癌症 癌症研究 免疫系统 内科学
作者
Luis A. Rojas,Zachary Sethna,Kevin C. Soares,Cristina Olcese,Nan Pang,Erin Patterson,Jayon Lihm,Nicholas Ceglia,Pablo Guasp,Alexander L. Chu,Rebecca Yu,Adrienne Kaya Chandra,Theresa Waters,Jennifer Jin Ruan,Masataka Amisaki,Abderezak Zebboudj,Zagaa Odgerel,George C. Payne,Evelyna Derhovanessian,Felicitas Müller
出处
期刊:Nature [Nature Portfolio]
卷期号:618 (7963): 144-150 被引量:1233
标识
DOI:10.1038/s41586-023-06063-y
摘要

Abstract Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a four-drug chemotherapy regimen (mFOLFIRINOX, comprising folinic acid, fluorouracil, irinotecan and oxaliplatin). The end points included vaccine-induced neoantigen-specific T cells by high-threshold assays, 18-month recurrence-free survival and oncologic feasibility. We treated 16 patients with atezolizumab and autogene cevumeran, then 15 patients with mFOLFIRINOX. Autogene cevumeran was administered within 3 days of benchmarked times, was tolerable and induced de novo high-magnitude neoantigen-specific T cells in 8 out of 16 patients, with half targeting more than one vaccine neoantigen. Using a new mathematical strategy to track T cell clones (CloneTrack) and functional assays, we found that vaccine-expanded T cells comprised up to 10% of all blood T cells, re-expanded with a vaccine booster and included long-lived polyfunctional neoantigen-specific effector CD8 + T cells. At 18-month median follow-up, patients with vaccine-expanded T cells (responders) had a longer median recurrence-free survival (not reached) compared with patients without vaccine-expanded T cells (non-responders; 13.4 months, P = 0.003). Differences in the immune fitness of the patients did not confound this correlation, as responders and non-responders mounted equivalent immunity to a concurrent unrelated mRNA vaccine against SARS-CoV-2. Thus, adjuvant atezolizumab, autogene cevumeran and mFOLFIRINOX induces substantial T cell activity that may correlate with delayed PDAC recurrence.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
怪味跳跳糖完成签到,获得积分10
刚刚
刚刚
2秒前
linzx009完成签到,获得积分10
2秒前
科研通AI2S的应助被61爱学习采纳,获得10
3秒前
自然的幻竹完成签到 ,获得积分10
4秒前
4秒前
日薪月亿发布了新的文献求助10
4秒前
完美世界的应助被Han采纳,获得10
4秒前
5秒前
zhu完成签到,获得积分10
5秒前
大南方完成签到,获得积分10
5秒前
充电宝的应助被坚定蘑菇采纳,获得10
5秒前
SciGPT的应助被椰子鸡采纳,获得10
6秒前
英俊的铭的应助被典雅的羿采纳,获得10
6秒前
6秒前
零点起步完成签到,获得积分10
6秒前
哆哆完成签到,获得积分10
6秒前
王一生完成签到,获得积分0
6秒前
王亚奇的应助被zzz采纳,获得10
7秒前
邱半仙发布了新的文献求助10
7秒前
7秒前
时尚发夹完成签到,获得积分10
8秒前
勤劳元瑶完成签到,获得积分10
8秒前
oldhope完成签到,获得积分10
9秒前
闪闪芹菜完成签到,获得积分10
9秒前
66666完成签到 ,获得积分10
9秒前
TCG完成签到,获得积分10
9秒前
会飞的猪完成签到,获得积分10
11秒前
11秒前
小马甲的应助被宋相甫采纳,获得10
11秒前
zhuchenglu发布了新的文献求助10
11秒前
11秒前
且行丶且努力完成签到,获得积分10
11秒前
12秒前
邱半仙完成签到,获得积分10
12秒前
12秒前
郭刚发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186480
求助须知:如何正确求助?哪些是违规求助? 9574861
关于积分的说明 21838499
捐赠科研通 7784154
什么是DOI,文献DOI怎么找? 3434775
关于科研通互助平台的介绍 2559164
邀请新用户注册赠送积分活动 2481565